Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of LAM561 Acid in Pediatric Patients with Malignant Glioma and Other Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

Study of LAM561 Acid in Pediatric Patients with Malignant Glioma and Other Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 2-hydroxyoleic acid (Primary)
  • Indications Glioma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Laminar Pharmaceuticals

    • Most Recent Events

    • 08 May 2024 Planned number of patients changed from 18 to 28.
    • 08 May 2024 Planned End Date changed from 1 Nov 2024 to 1 Sep 2025.
    • 08 May 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Jun 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top